Lupus & antiphospholipid syndrome
Epidemiology changes in systemic lupus erythematosus in Italy: the EASIEST study
Authors' conclusion
Over a decade, this GP-based study shows an increase in SLE prevalence and incidence within participating practices, accompanied by evolving therapeutic strategies and an increasing proportion of patients off treatment, including glucocorticoids.
Study context
- Population
- Systemic lupus erythematosus (SLE) cases identified among general practitioner (GPs) in the Florence District, Tuscany, Italy
- Exposure
- 2022 vs 2010
- Outcome
- Changes in SLE incidence and prevalence
- Follow-up
- 2010 vs 2022
Methodological detailstwo cross-sectional surveys (2010 vs 2022), GP-based
- Two cross-sectional surveys (2010 vs 2022)
- GP-based
Main finding
As reported in the abstract
| Group | Value | Prevalence per 100 000 persons |
|---|---|---|
| 2010 | 5.4 per 100 000 person-years | 75 |
| 2022 | 10.9 per 100 000 person-years | 120 |
Value
20105.4 per 100 000 person-years
202210.9 per 100 000 person-years
Prevalence per 100 000 persons
201075
2022120
Observational data: associations, not effects.
Further findings
Renal involvement · 2010 vs 2022
- Renal involvement declined
- 22% to 16%
Biologic therapy use
- Use of biologic therapies grew substantially over time, while GC remained pivotal in management
Patients not receiving any treatment (GC included)
- Proportion of patients not receiving any treatment (GC included) increased
Ethnic composition
- Ethnic composition of the SLE cohort remained largely stable, with most patients of Caucasian origin
Original publication
Epidemiology changes in systemic lupus erythematosus in Italy: the EASIEST study. Lupus Sci Med. Published 2 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →